Effect of Tong-Xie-Yao-Fang in the Treatment of CD in remission with Liver Depression and Spleen Deficiency during IFX treatment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048561

Enrollment

Unknown

Registered

2021-07-10

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn disease

Interventions

control group:IFX treatment

Experimental group:IFX combined with Tong-Xie-Yao-Fang

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. CD patients have a clinical response in the 10th week after completing IFX induction therapy (?CDAI>=70 points compared with the baseline period of treatment); 2. IFX treatment course >= 1 year; 3. Clinical remission in the 14th week after IFX induction therapy (CDAI<150 points); 4. No severe cardiac insufficiency, no severe pulmonary dysfunction, and basically normal liver and kidney functions.

Exclusion criteria

Exclusion criteria: 1. Combined nutritional therapy and hormone therapy; 2. Those with other major internal diseases such as respiratory, digestive, blood, cardiovascular, and endocrine diseases.

Design outcomes

Primary

Measure	Time frame
Clinical symptom score;	—

Countries

China

Contacts

Public ContactFan yihong

First Affiliated Hospital of Zhejiang Chinese Medical University

lemon20050928@163.com+86 13957104510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026